Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Change in Account Payables (2020 - 2025)

Barinthus Biotherapeutics' Change in Account Payables history spans 6 years, with the latest figure at -$348000.0 for Q4 2025.

  • For Q4 2025, Change in Account Payables rose 24.35% year-over-year to -$348000.0; the TTM value through Dec 2025 reached -$2.2 million, down 345.21%, while the annual FY2025 figure was -$2.2 million, 345.21% down from the prior year.
  • Change in Account Payables reached -$348000.0 in Q4 2025 per BRNS's latest filing, up from -$1.0 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $2.3 million in Q3 2023 to a low of -$3.8 million in Q4 2023.
  • Average Change in Account Payables over 5 years is -$353500.0, with a median of -$492000.0 recorded in 2024.
  • Peak YoY movement for Change in Account Payables: surged 975.44% in 2022, then crashed 480.26% in 2023.
  • A 5-year view of Change in Account Payables shows it stood at -$114000.0 in 2021, then soared by 975.44% to $998000.0 in 2022, then plummeted by 480.26% to -$3.8 million in 2023, then soared by 87.88% to -$460000.0 in 2024, then rose by 24.35% to -$348000.0 in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Change in Account Payables are -$348000.0 (Q4 2025), -$1.0 million (Q3 2025), and $342000.0 (Q2 2025).